AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20110140 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed formula feeding
Number of subjects: 833
Study 20110140 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula
Number of subjects: 833
Study 18596969 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC containing 0.3% FGF-2
Number of subjects: 74
Study 18596969 — intervention group
Group type: COMPARATOR
Intervention: HPC with no FGF-2 (Group P)
Number of subjects: 74
Study 18596969 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC containing 0.1% FGF-2 (Group M)
Number of subjects: 74
Study 18596969 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC containing 0.03% FGF-2 (Group L)
Number of subjects: 74
Study 16858953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (aspirin 300 mg/d + dipyridamole 75 mg thrice a day)
Number of subjects: 38
Study 16858953 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (300 mg/d)
Number of subjects: 38
Study 12242455 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care (systemic education)
Number of subjects: 56
Study 12242455 — intervention group
Group type: COMPARATOR
Intervention: Individual consultations and education (control)
Number of subjects: 56
Study 10638394 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg oral doses of amlodipine (reference formulation)
Number of subjects: 16
Study 10638394 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg oral doses of amlodipine (test formulation)
Number of subjects: 16
Study 7490595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepayment of $5 along with the mailed survey
Number of subjects: 400
Study 7490595 — intervention group
Group type: COMPARATOR
Intervention: Promise of $5 on return of a completed survey
Number of subjects: 400
Study 1788636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high streptokinase therapy
Number of subjects: 0
Study 1788636 — intervention group
Group type: COMPARATOR
Intervention: Conventional streptokinase dosage
Number of subjects: 0
Study 7270985 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injections of ragweed antigen
Number of subjects: 9
Study 7270985 — intervention group
Group type: COMPARATOR
Intervention: Monthly injections of ragweed antigen
Number of subjects: 9
Study 30672255 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-separated moxibustion combined with sulfasalazine enteric-coated tablets
Number of subjects: 64
Study 30672255 — intervention group
Group type: COMPARATOR
Intervention: Conventional moxibustion combined with sulfasalazine enteric-coated tablets
Number of subjects: 64
Study 27776560 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine for 1 year
Number of subjects: 31
Study 25488040 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion within 90 minutes of hospital contact
Number of subjects: 337
Study 25488040 — intervention group
Group type: EXPERIMENTAL
Intervention: Median door-to-balloon (D2B) time
Number of subjects: 337
Study 25488040 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from hospital contact to informed consent by region
Number of subjects: 337
Study 24112528 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% N2O added to 60-minute CO2 pneumoperitoneum
Number of subjects: 0
Study 24112528 — intervention group
Group type: COMPARATOR
Intervention: 10% N2O added to CO2 pneumoperitoneum
Number of subjects: 0
Study 24112528 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood (1 mL)
Number of subjects: 0
Study 24112528 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 0
Study 21044117 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone levels before adrenalectomy (235.0 ± 51.1 pg/ml)
Number of subjects: 6
Study 21044117 — intervention group
Group type: EXPERIMENTAL
Intervention: Na(+) ‐K(+) ‐ATPase activity before adrenalectomy
Number of subjects: 6
Study 21044117 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Na(+) ‐K(+) ‐ATPase activity with plasma aldosterone levels
Number of subjects: 6
Study 18362933 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0
Study 16547688 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (1 microg/day for 7 days)
Number of subjects: 21
Study 16547688 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone repletion (450 microg per day)
Number of subjects: 21
Study 16547688 — intervention group
Group type: COMPARATOR
Intervention: Phylloquinone depletion (4-week)
Number of subjects: 21
Study 12968960 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (4 ml) applied to wound surfaces and under the flap
Number of subjects: 54
Study 12968960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 54
Study 11068889 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-alone cognitive-behavioral treatment
Number of subjects: 36
Study 11068889 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cognitive-behavioral treatment
Number of subjects: 36
Study 11068889 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 36
Study 11068889 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-completed measures and clinician ratings of global functioning
Number of subjects: 36
Study 9160652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 9160652 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg)
Number of subjects: 0
Study 1358037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 39
Study 1358037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3882619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast agent (iohexol)
Number of subjects: 273
Study 3882619 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast agent (sodium methylglucamine diatrizoate)
Number of subjects: 273
Study 30994776 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐office bleaching with two applications of 35% hydrogen peroxide (HP) (20 minutes), followed by at‐home bleaching with 10% carbamide peroxide (CP) (2 hours/day for 16 days)
Number of subjects: 80
Study 30994776 — intervention group
Group type: EXPERIMENTAL
Intervention: Same protocol as G1, plus desensitizing toothpaste
Number of subjects: 80
Study 30994776 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐office bleaching with 35% HP and one application of placebo gel (20 minutes), followed by at‐home bleaching with 10% CP (2 hours/day for 16 days)
Number of subjects: 80
Study 30994776 — intervention group
Group type: EXPERIMENTAL
Intervention: Same protocol as G3, plus desensitizing toothpaste
Number of subjects: 80
Study 29764190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 1400
Study 29764190 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin with or without aztreonam
Number of subjects: 1400
Study 26990892 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose melphalan followed by autologous transplantation (HDM/ASCT)
Number of subjects: 358
Study 26990892 — intervention group
Group type: COMPARATOR
Intervention: Tandem high-dose melphalan followed by autologous transplantation (HDM/ASCT)
Number of subjects: 358
Study 24506834 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 66
Study 24506834 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 66
Study 23519436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg kg‐1
Number of subjects: 225
Study 23519436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg kg‐1
Number of subjects: 225
Study 23519436 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 225
Study 21048963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose Sulfate 6% (CS)
Number of subjects: 0
Study 21048963 — intervention group
Group type: COMPARATOR
Intervention: Quality control guidelines
Number of subjects: 0
Study 18387931 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg daily)
Number of subjects: 839
Study 18387931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 839
Study 16794097 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB assay in group 2 (moderately injured patients with ISS >15)
Number of subjects: 92
Study 16794097 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB assay in group 1 (mildly injured patients with ISS <15)
Number of subjects: 92
Study 16794097 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers)
Number of subjects: 92
Study 12745983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling with a schoolbag (6 kg)
Number of subjects: 20
Study 12745983 — intervention group
Group type: COMPARATOR
Intervention: Cycling without a schoolbag
Number of subjects: 20
Study 11679528 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (leuprolide acetate depot, 3.75 mg, monthly i.m. injections for 3 months)
Number of subjects: 89
Study 11679528 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (no treatment)
Number of subjects: 89
Study 11679528 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue
Number of subjects: 89
Study 11679528 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 89
Study 9706454 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy
Number of subjects: 0
Study 9706454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 9706454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8169405 — intervention group
Group type: EXPERIMENTAL
Intervention: cold‐recombinant, trivalent influenza vaccine
Number of subjects: 22
Study 3127050 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 5 mg b.i.d.
Number of subjects: 96
Study 3127050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31248064 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐LCCT
Number of subjects: 40
Study 31248064 — intervention group
Group type: COMPARATOR
Intervention: TT
Number of subjects: 40
Study 28270737 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Face Mask (TFM)
Number of subjects: 48
Study 28270737 — intervention group
Group type: COMPARATOR
Intervention: Oronasal Mask (ONM)
Number of subjects: 48
Study 25809565 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telehealth
Number of subjects: 52
Study 25809565 — intervention group
Group type: COMPARATOR
Intervention: In-person prolonged exposure
Number of subjects: 52
Study 23517885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.375 mg/day titrated to 2.25 mg/day)
Number of subjects: 39
Study 23517885 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day)
Number of subjects: 39
Study 23517885 — intervention group
Group type: COMPARATOR
Intervention: Combination of pramipexole and escitalopram
Number of subjects: 39
Study 21803570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CAIRO study)
Number of subjects: 1526
Study 21803570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus targeted therapy (CAIRO2 study)
Number of subjects: 1526
Study 19538647 — intervention group
Group type: EXPERIMENTAL
Intervention: Online communication with 'Informed Supporters', people who had been managing their bipolar disorder effectively for 2 years or more, as part of an online psycho-education programme.
Number of subjects: 26
Study 16679991 — intervention group
Group type: EXPERIMENTAL
Intervention: Steadiness training with light loads (30% of 1-RM, 10 reps per set, 3 sets per session, 3 sessions per week for 16 weeks)
Number of subjects: 21
Study 16679991 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 subjects)
Number of subjects: 21
Study 16679991 — intervention group
Group type: EXPERIMENTAL
Intervention: Steadiness training
Number of subjects: 21
Study 14648127 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) trial
Number of subjects: 10
Study 14648127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna (SAU) trial
Number of subjects: 10
Study 14648127 — intervention group
Group type: EXPERIMENTAL
Intervention: Face cooling during exercise (CON(FAN) and SAU(FAN))
Number of subjects: 10
Study 11371411 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SE (structured educational program emphasizing self-capacity to manage asthma exacerbations)
Number of subjects: 126
Study 11371411 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SE
Number of subjects: 126
Study 11371411 — intervention group
Group type: COMPARATOR
Intervention: Group C (control; usual treatment)
Number of subjects: 126
Study 11371411 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LE (limited education; teaching of the inhaler technique plus self-action plan)
Number of subjects: 126
Study 9228363 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise protocol
Number of subjects: 21
Study 9228363 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise protocol
Number of subjects: 21
Study 9228363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 21
Study 7965250 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity support program participants
Number of subjects: 220
Study 7965250 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants of the maternity support program
Number of subjects: 220
Study 29016474 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell (KB) exercise
Number of subjects: 17
Study 29016474 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control trial
Number of subjects: 17
Study 31219668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic with person-centred care and frequent visits
Number of subjects: 70
Study 31219668 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 70
Study 29425904 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-AzeFlu
Number of subjects: 82
Study 29425904 — intervention group
Group type: EXPERIMENTAL
Intervention: LORA/INFP
Number of subjects: 82
Study 29425904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 28001244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded molars (using composite resin)
Number of subjects: 32
Study 28001244 — intervention group
Group type: COMPARATOR
Intervention: Banded molars (cemented with glass ionomer)
Number of subjects: 32
Study 28001244 — intervention group
Group type: COMPARATOR
Intervention: Banded lower molars
Number of subjects: 32
Study 28001244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded lower molars
Number of subjects: 32
Study 25214548 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated RLN injury group (n = 26)
Number of subjects: 34
Study 25214548 — intervention group
Group type: COMPARATOR
Intervention: Concurrent SLN/RLN injury group (n = 8)
Number of subjects: 34
Study 22759326 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical concomitant therapy (PPI, amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg; all drugs b.i.d.)
Number of subjects: 298
Study 22759326 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy for clarithromycin-susceptible H. pylori
Number of subjects: 298
Study 22759326 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy for clarithromycin-resistant strains
Number of subjects: 298
Study 20922563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 55
Study 20922563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 18555939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminaftone 75 mg TID for 12 weeks
Number of subjects: 24
Study 16052297 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 75
Study 16052297 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 75
Study 16052297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DES and BMS
Number of subjects: 75
Study 12449290 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial antioxidant supplement (dried fruit and vegetable extracts, fortified with antioxidants, gummy-type candy), taken in 2 doses per day for 21 days
Number of subjects: 39
Study 12449290 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken in 2 doses per day for 21 days
Number of subjects: 39
Study 10366112 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose D-penicillamine (750-1,000 mg/day)
Number of subjects: 134
Study 10366112 — intervention group
Group type: COMPARATOR
Intervention: Low-dose D-penicillamine (125 mg every other day)
Number of subjects: 134
Study 8808186 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 58
Study 8808186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CTX)
Number of subjects: 58
Study 8808186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 58
Study 8808186 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 2042095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus and antroseromuscular flap-preserving subtotal gastrectomy (PAFPG)
Number of subjects: 125
Study 7025719 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cisplatin (120 mg/m2) with vindesine
Number of subjects: 85
Study 7025719 — intervention group
Group type: COMPARATOR
Intervention: Low dose cisplatin (60 mg/m2) with vindesine
Number of subjects: 85
Study 31688572 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 vaginal inserts (4, 10, or 25 μg)
Number of subjects: 695
Study 31688572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study 31688572 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 vaginal inserts
Number of subjects: 695
Study 28903965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) plus low-dose corticosteroids
Number of subjects: 41
Study 28903965 — intervention group
Group type: COMPARATOR
Intervention: Low-dose corticosteroids (monotherapy)
Number of subjects: 41
Study 27236596 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and self-care group (ESG)
Number of subjects: 42
Study 27236596 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (EG)
Number of subjects: 42
Study 27236596 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 24613333 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II LVAD (PA group)
Number of subjects: 247
Study 24613333 — intervention group
Group type: COMPARATOR
Intervention: Historical comparison group (TR group)
Number of subjects: 247
Study 22041126 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity aerobic training (HI: 80% maximum heart rate, n=10)
Number of subjects: 31
Study 22041126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity aerobic training (LI: 55% of maximum heart rate, n=10)
Number of subjects: 31
Study 22041126 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 31
Study 20195641 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thyroidectomy (MIVAT), n = 23
Number of subjects: 49
Study 20195641 — intervention group
Group type: COMPARATOR
Intervention: Traditional thyroidectomy (OPEN), n = 26
Number of subjects: 49
Study 17670916 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution (75 g in 300 ml water)
Number of subjects: 17
Study 17670916 — intervention group
Group type: COMPARATOR
Intervention: Water (300 ml)
Number of subjects: 17
Study 15591328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg(‐1)
Number of subjects: 22
Study 15591328 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study 11893258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellophane patch
Number of subjects: 30
Study 11893258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin ointment seal
Number of subjects: 30
Study 11893258 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plug (Control)
Number of subjects: 30
Study 9568918 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-locked echo-tracking method
Number of subjects: 95
Study 7607777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention including a 10-minute educational session and a nine-step self-help manual.
Number of subjects: 0
Study 7607777 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care
Number of subjects: 0
Study 2220138 — intervention group
Group type: EXPERIMENTAL
Intervention: New trocar-cannula combination (10 French)
Number of subjects: 149
Study 2220138 — intervention group
Group type: COMPARATOR
Intervention: Standard Cystofix system (10 French)
Number of subjects: 149
Study 371561 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (250 mg b.i.d.)
Number of subjects: 12
Study 371561 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg b.i.d.)
Number of subjects: 12
Study 371561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30897686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriophage consumption for 28 days
Number of subjects: 0
Study 28696047 — intervention group
Group type: COMPARATOR
Intervention: Food Safety Guidelines (FSGs)
Number of subjects: 150
Study 28696047 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic Diet + Food Safety Guidelines (ND + FSGs)
Number of subjects: 150
Study 26482247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium reduced from 138mmol/l to 136mmol/l
Number of subjects: 64
Study 26482247 — intervention group
Group type: COMPARATOR
Intervention: Dialysate sodium remained at 138mmol/l
Number of subjects: 64
Study 24935363 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide-cisplatin alternating with vinorelbine-cisplatin (EP-NP)
Number of subjects: 82
Study 24935363 — intervention group
Group type: COMPARATOR
Intervention: Etoposide-cisplatin (EP)
Number of subjects: 82
Study 23204096 — intervention group
Group type: COMPARATOR
Intervention: 35 percent calcium-free (CF) hydrogen peroxide gel
Number of subjects: 40
Study 23204096 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 percent calcium-containing (CC) hydrogen peroxide gel
Number of subjects: 40